Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%

MT Newswires Live

2025/05/26

Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.

The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.

The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.

Shares of the pharma manufacturer were down over 3% in recent trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538121869"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538121869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538121869?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-26 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538121869","market":"us","top_or_hot":-1,"title":"Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.</p><p>The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.</p><p>The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.</p><p>Shares of the pharma manufacturer were down over 3% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-26 13:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.</p><p>The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.</p><p>The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.</p><p>Shares of the pharma manufacturer were down over 3% in recent trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"遠大醫藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2538121869","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538121869","pubTimestamp":1748237333,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Grand Pharmaceutical Group  said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.Shares of the pharma manufacturer were down over 3% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药"},"translate_title":"远大医药治疗蠕形螨睑缘炎在澳门获批；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9},"content_text":"Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.Shares of the pharma manufacturer were down over 3% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}